Q3 2025
Released Nov 7, 2025, before the open
10-Q filed Nov 7, 2025, 38 days after period end · 0001628280-25-050422
Q3 2025 · 10-Q
Revenue$1.23M$1.23M +486.1% vs Q3 2024+9.9% vs Q2 2025
Net Income-$50.58M-$50.58M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.32-$0.32 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$53,973,000N/M
Operating Cash Flowderived-$35,039,000N/M
Free Cash Flowderived-$35,286,000N/M
Margins · derived
Operating margin-4406.0%+21542.4 pt vs Q3 2024
Net margin-4129.1%+20999.1 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $1.23M | $209.00K | $0.00 | — |
| Net Income | -$50.58M | -$52.52M | -$50.71M | -$29.35M |
| EPS Diluted | -$0.32 | -$0.44 | -$0.55 | -$1.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR